Emily M. Leproust - 21 Feb 2025 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role: Chief Executive Officer, Director
Signature: /s/ Dennis Cho, as Attorney-in-Fact for Emily M. Leproust
Issuer symbol: TWST
Transactions as of: 21 Feb 2025
Net transactions value: -$123,254
Form type: 4
Filing time: 25 Feb 2025, 16:05:09 UTC
Previous filing: 05 Feb 2025
Next filing: 10 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TWST	Common Stock	Sale	$123,254	-2,790	-0.42%	$44.18	665,094	21 Feb 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TWST	Employee Stock Option (right to buy)						0	21 Feb 2025	Common Stock	0	$5.95	Direct	F3
holding	TWST	Employee Stock Option (right to buy)						150,879	21 Feb 2025	Common Stock	0	$8.82	Direct	F4
holding	TWST	Employee Stock Option (right to buy)						266,539	21 Feb 2025	Common Stock	0	$26.66	Direct	F5
holding	TWST	Employee Stock Option (right to buy)						131,290	21 Feb 2025	Common Stock	0	$23.33	Direct	F6
holding	TWST	Employee Stock Option (right to buy)						64,950	21 Feb 2025	Common Stock	64,950	$67.85	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2	Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3	The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4	The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5	20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F6	25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F7	Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.